Image

Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers

Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Individuals with multiple myeloma (MM) are vulnerable because of the effects of systemic organ damage and the side effects of treatment. A decline in patients' health-related quality of life (HRQoL) and a compromised participation in everyday life was reported. The diagnosis of MM negatively affects the principal informal caregiver. This is a concurrent exploratory mixed methods study that involves the use of a quantitative and a qualitative approach. For the quantitative study, aims are to describe any possible relation between the identified factors with HRQoL and participation in individuals with MM and with reactions to caring and self-efficacy of caregivers. For the qualitative study, aims are to investigate "how" and "why" the disease impacts the daily life of individuals with MM and their caregivers. The final analyses will be based on the comparison of the results of the quantitative phase and the results of the qualitative phase.

Description

MM is a hematological disease caused by an uncontrolled proliferation of plasma cells. Individuals with MM are vulnerable because of the effects of systemic organ damage and the side effects of treatment. A decline in patients' functional status, the deterioration of health-related quality of life (HRQoL) and a compromised participation in everyday life was reported. Moreover, the diagnosis of MM occurs within the context of a family and it negatively affects the principal informal caregiver.

According to the International Classification of Functioning, Disability and Health, participation in daily life plays a key role in rehabilitation as it confers a sense of normalcy to life. Comprehensive rehabilitation intervention aiming at improving HRQoL and facilitating participation has never been implemented with this aim.

From previous systematic reviews, it emerges that patient reported outcomes (PRO) of individuals with MM have been studied mainly in randomized clinical trials, but also few observational studies have been published, conducting also in Italy. In the province of Reggio Emilia, population-based data concerning the HRQoL of individuals with MM have never been collected, as well as for their caregivers. Needs related to participation in everyday life of individuals with MM and their caregivers were mainly studied through qualitative approach.

Although qualitative data are essential in describing a phenomenon, it is currently not possible to quantify the degree of loss of participation in everyday life or to identify patients most at risk of social isolation. As a counterpart, qualitative approach may explain those situations that quantitative approach cannot verify (e.g., reasons behind conditions of social vulnerability). For these reasons, it seems appropriate to explore the patients' perceived HRQoL and participation from both quantitative and qualitative perspectives, as well as the caregivers' burden, by integrating these data. In this study, needs and difficulties in accomplishing the relevant activities and roles as well as the description of factors that act as facilitators or barriers to HRQoL and participation will be identified to screen patients that might benefit most from rehabilitation. Based on these data, comprehensive and tailored rehabilitation may be planned in future studies and tested for its impact on HRQoL and participation.

This is a concurrent exploratory mixed methods study that involves the use of a quantitative and a qualitative approach. The quantitative is the main study, while the qualitative is the sub-study. Participants of the qualitative study will be a sub-group of those recruited in the quantitative study. In this mixed methods study, we will recruit individuals with MM and caregivers.

For the quantitative study, aims are to describe any possible relation between the identified factors with HRQoL and participation in individuals with MM and with reactions to caring and self-efficacy of caregivers. Data collection will be performed through an individual semi-structured interview conducted in person, remotely or through self-administration, based on participant preference and availability.

As for individuals with MM, the semi-structured interview will consist in the collection of sociodemographic and work-related characteristics, while the side effects of treatments, the needs perceived from this population and the outcomes of interest will be collected through validated assessment tools. Disease-related factors will be retrieved from medical records.

As for caregivers, the semi-structured interview will consist in the collection of sociodemographic and work-related characteristics, while the outcomes of interest will be collected through validated assessment tools. The analyses of the quantitative phase will be carried out at the end of the quantitative data collection.

Qualitative Sub-Study To complement the findings of the primary quantitative study, a qualitative sub-study will be conducted to deepen the understanding of the disease-related experiences of individuals with MM and their informal caregivers and its consequences on daily life.

This qualitative sub-study is embedded within the larger concurrent exploratory mixed methods design. Participants in the qualitative phase will be a purposeful sub-sample of those already enrolled in the quantitative study, selected to ensure variation in the line of therapy (LOT), gender, and occupational status. Inclusion will aim to represent diverse patient and caregiver experiences.

In this qualitative sub-study, open-ended questions will be asked to participants by using interview guides, one for individual with MM and one for caregiver. Before conducting the qualitative interviews, a preliminary phase will be organized where researchers will involve expert patients and caregivers to support them in defining themes and questions of the interview guide. As an example, questions of the final interview guide will be: "Could you describe your life experience and your health after being diagnosed with multiple myeloma? How do the symptoms and the disease affect your daily life? What does caring for your loved one mean to you?".

Data will be collected through semi-structured interviews conducted in person or via video call, based on participant preference and availability. All interviews will be audio-recorded, transcribed verbatim, and analyzed through the reflexive thematic analysis using an inductive approach associated to open coding. Analysis will be iterative and involve multiple researchers to ensure inter-rater reliability of the coding procedure and the methodological rigor of the analysis.

The qualitative phase analyses will be carried out at the end of each interview because, based on the themes that will emerge from each interview, we will understand when to stop recruiting.

The final analyses of the mixed methods study will be based on the comparison of the results of the quantitative phase and the results of the qualitative phase. The comparison will be performed using data triangulation or other methods depending on the level of agreement of results of both phases. From the comparison we would like to understand to what extent the results of the qualitative study confirm those of the quantitative study or if the themes that we will develop from the qualitative interviews will show other issues. This merging of the results will allow us to define a set of criteria to identify those individuals with MM and caregivers in need of support and who could benefit more from a tailored rehabilitation intervention.

Eligibility

Inclusion criteria for individuals with MM will be:

  1. diagnosis of MM
  2. adulthood (≥ 18 years)
  3. in treatment (LOT I, II, or ≥ III) at the Hematology Unit
  4. speak Italian fluently

Exclusion Criteria:

Comorbidities that limit collaboration (e.g., dementia, severe psychiatric disorders).


Inclusion criteria for caregiver will be:

  1. having a loved one (individual with MM) who have participated in the quantitative phase
  2. being the primary informal caregiver
  3. adulthood (≥ 18 years)
  4. speak Italian fluently

Study details
    Multiple Myeloma (MM)
    Hematologic Neoplasm

NCT07014865

Azienda USL Reggio Emilia - IRCCS

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.